Filing Details
- Accession Number:
- 0001126234-14-000025
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-01-06 19:48:03
- Reporting Period:
- 2014-01-02
- Filing Date:
- 2014-01-06
- Accepted Time:
- 2014-01-06 19:48:03
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1126234 | Newlink Genetics Corp | (NLNK) | Pharmaceutical Preparations (2834) | 421491350 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1512113 | Jr. J. Charles Link | C/O Newlink Genetics Corp. 2503 South Loop Dr., Suite 5100 Ames IA 50010 | Chairman Of The Board And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-01-02 | 12,500 | $0.00 | 861,987 | No | 4 | A | Direct | |
Common Stock | Acquisiton | 2014-01-02 | 23,000 | $0.00 | 884,987 | No | 4 | A | Direct | |
Common Stock | Disposition | 2014-01-03 | 11,000 | $21.97 | 873,987 | No | 4 | S | Direct | |
Common Stock | Disposition | 2014-01-06 | 9,000 | $22.44 | 864,987 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | A | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2014-01-02 | 108,750 | $0.00 | 108,750 | $21.38 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
108,750 | 2024-01-01 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 10,000 | Indirect | By Spouse |
Common Stock | 139 | Indirect | By Spouse's IRA |
Footnotes
- Represents shares issued as restricted stock units ("RSUs") under the Issuer's 2009 Equity Incentive Plan (the "Plan") that were received as an award, for no consideration. 100% of the RSUs vest immediately.
- Represents shares issued as RSUs under the Plan that were received as an award, for no consideration. The RSUs vest in a series of four successive annual installments beginning on January 2, 2015, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on 6/17/2013.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.77 to $22.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote 4 to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.25 to $22.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnote 5 to this Form 4.
- Grant to the Reporting Person of a stock option under the Plan. The option vests and becomes exercisable in a series of 48 successive equal monthly installments beginning on January 2, 2014, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan. The option expires ten years after the date of grant.